Lilly's $3.35 billion InnoCare license is $100 million near term

Eli Lilly signed Beijing-based InnoCare Pharma to discover and advance compounds against as many as five drug targets, the Chinese company said Thursday. InnoCare is eligible for up to $100 million in upfront and near-term payments, about $3.25 billion in development and commercial milestones, and single-digit tiered royalties on annual net product sales. Add the two cash figures and the maximum is $3.35 billion. Almost all of it is conditional.

The contract is a small discovery option on a $1.12 trillion company. It reaches healthcare funds only because those funds already hold Lilly in size.

The $100 million near-term package is 3.0% of the $3.35 billion ceiling. The other 97% is milestones. SRS Acquiom, which tracks whether acquisition earnouts actually get paid, found that 19% of biopharma earnout dollars due by mid-2025, $6.5 billion of $34.8 billion, were paid, a figure from buyouts rather than licenses.

Five targets, none of them named

InnoCare, listed in Hong Kong as 09969 and in Shanghai as 688428, said it will use its discovery platform on “up to five targets” for “critical unmet medical needs.” Lilly is paying for a discovery platform, not a named molecule, and the release discloses neither the targets nor who keeps China rights, development, manufacturing, or sales. InnoCare describes itself as a commercial-stage company focused on cancer and autoimmune disease. That is the company’s business, not a disclosed limit of the Lilly contract.

Platform and discovery-stage deals in the first half of 2026 carried a median disclosed upfront of $62 million. Co-founder, chairwoman and chief executive Jasmine Cui called Lilly “a global pharmaceutical leader” and said InnoCare wanted to expand its “partnership and innovation footprint.” Lilly did not issue a parallel statement.

InnoCare already reported about RMB 8.4 billion in cash and related accounts as of June 30 and a first-half profit of RMB 239.7 million on revenue of RMB 1.1 billion, up 55.5% from a year earlier. The Lilly cash is a bonus on a funded, now-profitable company, not a rescue.

A discovery license, not a named-asset sale

This is not the check Pfizer wrote last year. Pfizer paid $1.25 billion upfront in May 2025 to license 3SBio’s SSGJ-707. AbbVie paid $650 million upfront in January for RemeGen’s RC148, a deal commonly put at $5.6 billion including milestones. AstraZeneca’s January pact with CSPC Pharmaceutical for experimental weight-loss programs has been reported at up to $18.5 billion. InnoCare is being paid to look, not to hand over a molecule already in the clinic.

The distinction matters because the political category is the same. Reuters put 2025 out-licensing by companies in greater China at a record $137.7 billion. In July, Reuters reported that state broadcaster CCTV, citing China’s National Medical Products Administration, said that on its count, first-half 2026 deal value had already reached 80% of 2025’s full-year total. Reuters, citing GlobalData, also reported that almost half of U.S. deals to license drugs from abroad in 2025 were with Chinese companies. Lilly’s InnoCare contract sits in that stream: Western pharma filling pipelines in China, with the large number printed first and the cash that actually moves printed in the footnote.

Lilly can afford the footnote. Second-quarter revenue rose 48% to $23.0 billion, driven by Mounjaro and Zepbound, and the company raised 2026 sales guidance to $85.0 billion to $87.0 billion. It has been buying as well as licensing. On August 31 it agreed to acquire privately held Merida Biosciences for up to $2.875 billion in cash to add autoimmune and allergy programs. The InnoCare license is an earlier bet, and a Chinese one. The habit is the same: spend obesity cash on the next pipeline.

Treasury has not closed the window

The BIOSECURE Act, signed into the fiscal 2026 defense bill on December 18, 2025, restricts federal agencies from procuring biotechnology equipment or services from designated “biotechnology companies of concern,” and from contracting with firms that use those products on federal work. It is a government-contracting rule. It does not, on its face, ban a private license between Lilly and InnoCare.

What could still change is the Treasury process. On September 18, Reuters reported that rules being drafted for pharmaceutical investment in China would likely preserve the ability to strike most licensing deals for Chinese drugs, according to three people briefed on the work. The sources said the rules have not been finalized, could still change if the president weighs in, and were unlikely to be unveiled before this week’s meeting with Xi. Western drugmakers have been urging the administration to keep that channel open.

None of that is a decision. It is the backdrop against which Lilly signed anyway. The Biotech Investment National Security Act, introduced in the Senate on August 6 by Sens. Elissa Slotkin and Pete Ricketts, would put pharmaceutical licenses with Chinese counterparties under Treasury review. It has not become law.

Hong Kong sold InnoCare; U.S. funds barely own it

InnoCare’s Hong Kong shares closed at HK$14.51, down 7.9%, after trading as high as HK$16.16, a 2.6% gain, and as low as HK$13.93. The company announced the deal during the Hong Kong session. Neither an InnoCare filing nor a Lilly statement explains why the stock went from a 2.6% gain to a 7.9% decline. One session does not settle the question.

Lilly was 2.9% higher at $1,184.54 as of 9:47 a.m. Eastern. That print also follows a separate Thursday event: the Food and Drug Administration approved Lilly’s once-weekly basal insulin for adults with type 2 diabetes. Do not read the New York move as a verdict on InnoCare.

The fund board is lopsided. Lilly is 15.2% of the Health Care Select Sector SPDR ETF AXLV, a $43 billion S&P 500 healthcare tracker graded A, and 23.1% of the iShares U.S. Pharmaceuticals ETF BIHE, a $1.16 billion basket of U.S. drugmakers graded B. The VanEck Pharmaceutical ETF APPH, graded A, holds Lilly at 20.5%. Those weights are the obesity franchise, not a five-target discovery contract. InnoCare is a rounding error in U.S. listed funds.

A holder of those healthcare funds already owns Lilly’s option on five unnamed programs, and the right to drop them if they fail. InnoCare’s share price is not in that package. The money that has to change hands is $100 million, not $3.35 billion.